MedTrace Logo

Validation of in Vitro Method for Anti-MCPyV Immunotherapy on Patients With Cutaneous Merkel Cell Carcinoma

NCT06780475 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 15

Last updated 2025-11-19

No results posted yet for this study

Summary

The aim of the study is to test and validate in vitro a cell therapy approach for MCPyV+ Merkel Cell Carcinoma patients.

Conditions

  • Merkel Cell Carcinoma of Skin

Sponsors & Collaborators

  • Institut National de la Santé Et de la Recherche Médicale, France

    collaborator OTHER_GOV

  • Assistance Publique - Hôpitaux de Paris

    lead OTHER

Principal Investigators

  • Astrid Blom, MD · Dermato-oncology Department, Ambroise Paré Hospital, APHP

  • Yassine Taoufik, MD, PhD · U1186 INSERM, PAUL BROUSSE Hospital, APHP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-05-27
Primary Completion
2027-05-31
Completion
2027-05-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06780475 on ClinicalTrials.gov